BIOSTEM TECHNOLOGIES NEW - BSEM STOCK NEWS

BioStem Technologies Inc. (OTC: BSEM) reported a strong financial performance for the year ending December 31, 2021, achieving net revenue of $4.341 million, a remarkable 80% increase from $2.415 million in 2020. The net loss shrank to ($1.408 million), down 44% from ($2.518 million) the previous year. The gross profit rose by 121% to $2.824 million. CEO Jason Matuszewski highlighted ongoing growth driven by the commercialization of the Vendaje product and anticipates continued growth in 2022, bolstered by product launches and an expanding commercial team.

BioStem Technologies (BSEM) reported impressive financial results for Q2 2021, with sales increasing by 306% to $970,511 compared to Q2 2020. Gross profit surged 1,348% to $455,723, representing 47% of sales. The net loss decreased by 47% year-over-year to $373,651. For the first half of 2021, sales rose 89% to $1,923,019 with a gross profit of $1,191,817, or 62% of sales. The company attributed this growth to an expanded sales force and increased adoption of its amniotic product portfolio.

BioStem Technologies (OTC PINK: BSEM) has partnered with Biologics Consulting to advance its investigational new drug (IND) candidates through the regulatory pipeline. With nearly 30 years of experience, Biologics Consulting has aided over 3,500 companies globally and contributed to more than 50 original INDs in the past four years. The collaboration aims to navigate the FDA’s Biologics License Application (BLA) process, enhancing BioStem's potential for product development in regenerative therapies.

BioStem Technologies, Inc. (OTC PINK: BSEM) announced that the Centers for Medicare and Medicaid Services (CMS) has approved a new Healthcare Common Procedure Coding System (HCPCS) Q-code (Q4252) for its VENDAJE product. This decision, effective October 1, 2021, enables Medicare claims processing for the product, enhancing reimbursement strategies. CEO Jason Matuszewski emphasized that this Q-code is a crucial step for providing better billing options for healthcare providers and patients, potentially leading to significant growth opportunities.

BioStem Technologies, Inc. (BSEM) reported its first quarter 2021 results, showcasing a 22% increase in sales to $952,508 compared to $777,365 in Q1 2020. The cost of sales decreased to $216,414, significantly improving the gross margin to 77.23%, up from 45.5% year-over-year. Net losses also fell by 25% to $292,782. Recent highlights include receiving FDA TRIP response for their VENDAJE™ allograft and expanding their scientific advisory board.

BioStem Technologies (OTC PINK: BSEM) announced the appointment of three new members to its Scientific Advisory Board (SAB) to enhance its focus on perinatal tissue regenerative therapies. The new members are Jeffrey Harrison, Daniel Shelly, and Shaun Opie, joining Chairman Kenneth Warrington. Their combined expertise spans pharmacology, regulatory strategies, and advanced therapeutics, which will support BioStem's innovative product development and market expansion. This strategic move aligns with BioStem's vision to reinforce its scientific foundations and improve its product portfolio.

BioStem Technologies (OTC PINK: BSEM) is expanding its national sales force to boost sales of its perinatal tissue allografts. This strategic move comes as elective surgeries resume post-COVID-19 shutdowns, increasing demand for regenerative therapies. BioStem will add experienced sales representatives in key regions: Northeast, Midwest, and Mountain Region. The company specializes in utilizing perinatal tissue for regenerative medicine, leveraging proprietary technologies to enhance patient outcomes and shareholder value.

BioStem Technologies, Inc. (OTC PINK: BSEM) reported significant growth in Q4 2020 with sales of $1,037,823, up 147% from $420,389 in Q4 2019. For fiscal 2020, total sales reached $2.5 million, down slightly from $2.6 million in 2019, while net loss improved to $2.4 million from $6.3 million. Operating expenses decreased by 44.2% due to reduced stock-based compensation, despite increased direct sales costs. The company anticipates continued revenue growth associated with the vaccine rollout and a positive response from the FDA regarding its amniotic membrane allograft, VENDAJE™.